Added to YB: 2024-06-07
Pitch date: 2024-06-06
CHRS [bullish]
Coherus Oncology, Inc.
-19.19%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Market Cap
$96.2M
Pitch Price
$1.72
Price Target
11.00 (+715%)
Dividend
N/A
EV/EBITDA
-4.12
P/E
1.95
EV/Sales
1.15
Sector
Biotechnology
Category
growth
Two Companies That Could Pay Off Big - Coherus BioSciences, Inc.
CHRS: Biosimilar biopharma focused on oncology & immunology. UDENYCA franchise at 25% market share, up from 11.5% YoY. LOQTORZI targets rare nasopharyngeal cancer with no alternatives. Despite risks, continued scaling could drive CHRS from $200M to $7-10B valuation.
Read full article (3 min)